Symbiotec Pharma

Not Rated
  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE899I01028
  • NSEID: SYMBIOTEC
  • BSEID: 544889
INR
1,598.75
-3.9 (-0.24%)
BSENSE

Nov 20

BSE+NSE Vol: 20533

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024

Compare Profit and Loss Results of Symbiotec Pharma
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
756.00
1,348.00
-592.00
-43.92%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
756.00
1,348.00
-592.00
-43.92%
Expenditure (Ex Depriciation)
Stock Adjustments
11.00
-3.00
14.00
466.67%
Raw Materials Consumed
288.00
830.00
-542.00
-65.30%
Power & Fuel Cost
0.00
49.00
-49.00
-100.00%
Employee Cost
119.00
217.00
-98.00
-45.16%
Operating Expenses
50.00
68.00
-18.00
-26.47%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
2.00
5.00
-3.00
-60.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
17.00
46.00
-29.00
-63.04%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
537.00
1,251.00
-714.00
-57.07%
Operating Profit (PBDIT) excl Other Income
219.00
97.00
122.00
125.77%
Other Income
32.00
112.00
-80.00
-71.43%
Operating Profit (PBDIT)
251.00
210.00
41.00
19.52%
Interest
16.00
10.00
6.00
60.00%
Profit before Depriciation and Tax
234.00
200.00
34.00
17.00%
Depreciation
38.00
45.00
-7.00
-15.56%
Profit Before Taxation & Exceptional Items
196.00
154.00
42.00
27.27%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
196.00
148.00
48.00
32.43%
Provision for Tax
50.00
36.00
14.00
38.89%
Profit After Tax
145.00
111.00
34.00
30.63%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
589.00
1,317.00
-728.00
-55.28%
Profit Available for appropriations
734.00
1,429.00
-695.00
-48.64%
Appropriations
734.00
1,429.00
-695.00
-48.64%
Equity Dividend (%)
0%
150%
-150.00
Earnings Per Share
133.35
7.29
126.06
1,729.22%
Profit And Loss - Net Sales
Net Sales 756.68 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 219.03 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024

Profit And Loss - Interest
Interest 16.65 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 145.83 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024